Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €157.49 EUR
Change Today -5.77 / -3.54%
Volume 65.0
As of 3:41 PM 04/30/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Connaught House

Fourth Floor

One Burlington Road

Dublin, 4

Ireland

Phone: 353 1 634 7800

Fax: 353 1 634 7850

Jazz Pharmaceuticals Public Limited Company, an international biopharmaceutical company, focuses on identifying, developing, and commercializing products that address unmet medical needs. Strategy The key elements of the company’s strategy include growing sales of the existing products in its portfolio, including by identifying new growth opportunities; acquiring additional differentiated products that are on the market or product candidates that are in late-stage development; and pursuing focused development of a pipeline of post-discovery differentiated product candidates. Operations The company has a portfolio of products and product candidates, with a focus in the areas of sleep and hematology/oncology. Xyrem (sodium oxybate) oral solution Xyrem (sodium oxybate) oral solution, the only product approved by the United States Food and Drug Administration (FDA), for the treatment of both cataplexy and excessive daytime sleepiness, or EDS, in patients with narcolepsy. The company promotes Xyrem in the United States through a specialty sales force of approximately 100 sales professionals dedicated to Xyrem. Xyrem is a controlled substance in the United States, subject to regulation by the U.S. Drug Enforcement Administration, or DEA, under the Controlled Substances Act, or CSA. Outside of the United States, UCB Pharma Limited, or UCB, has an exclusive license to market Xyrem for the treatment of narcolepsy in 54 countries and sells the product in 19 countries. The company has licensed to Valeant Canada Limited, or Valeant, the Canadian marketing rights to Xyrem for the treatment of narcolepsy. It supplies Xyrem to UCB and Valeant. Erwinaze/Erwinase (asparaginase Erwinia chrysanthemi) Erwinaze (asparaginase Erwinia chrysanthemi), a treatment approved in the United States and in certain markets in Europe (where it is marketed as Erwinase) for patients with acute lymphoblastic leukemia, or ALL, who have developed hypersensitivity to E. coli-derived asparaginase. Erwinaze was originally developed by Public Health England, or PHE, a U.K. national executive agency. In December 2014, the FDA approved a supplemental biologics license application for administration of Erwinaze through intravenous infusion in conjunction with chemotherapy. Outside of the United States, Erwinaze is sold under the name Erwinase pursuant to marketing authorizations, named patient programs, temporary use authorizations or similar authorizations in multiple countries in Europe and elsewhere. The company promotes Erwinaze in the United States through a specialty sales force of approximately 25 sales professionals. It provides reimbursement support through its JumpStart Access & Reimbursement Solutions program, a dedicated Erwinaze call center. Its field-based and office-based reimbursement team provides additional reimbursement support, dealing specifically with the more complex needs of physicians and payors. In Europe and elsewhere around the world, Erwinase is sold pursuant to marketing authorizations, named patient programs, temporary use authorizations or similar authorizations. The company’s hematology and oncology sales force outside of the United States has approximately 25 hematology field specialists responsible for promoting Erwinase and Defitelio in approved markets where it commercializes these products. Erwinaze is exclusively licensed to the company for worldwide marketing, sales and distribution by PHE, which also manufactures the product for it. PHE is its sole supplier for Erwinaze. The company obligated to make tiered royalty payments to PHE based on worldwide net sales of Erwinaze and Erwinase. In Europe and elsewhere around the world, Erwinase is sold pursuant to marketing authorizations, named patient programs, temporary use authorizations or similar authorizations. The company’s hematology and oncology sales force outside of the United States has approximately 25 hematology field specialists responsible for promoting Erwinase and Defitelio in approved markets where it commercializes these products. Erwinaze is exclusively licensed to the company for worldwide marketing, sales and distri

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
J7Z:GR €157.49 EUR -5.77

J7Z Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $43.00 USD +1.36
Alkermes PLC $59.10 USD +3.73
BioMarin Pharmaceutical Inc $115.92 USD +3.87
Impax Laboratories Inc $46.38 USD +1.12
Incyte Corp $98.28 USD +1.12
View Industry Companies
 

Industry Analysis

J7Z

Industry Average

Valuation J7Z Industry Range
Price/Earnings 100.0x
Price/Sales 9.3x
Price/Book 8.0x
Price/Cash Flow 59.3x
TEV/Sales 7.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JAZZ PHARMACEUTICALS PLC, please visit www.jazzpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.